DexCom and Abbott settle global patent litigation, enter royalty-free cross-license

DEXCOM INC

DexCom and Abbott signed a settlement and patent cross-license agreement on Dec 20, 2024.
Each party grants the other a worldwide, royalty-free, non-exclusive license to certain analyte-sensing patents.
No royalties or any financial compensation are required under the agreement.
Both parties entered a covenant not to sue until December 20, 2034.
Non-challenge provisions apply to licensed patents for varying periods.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.